Targeting epigenetic modifiers and splicing regulators together may offer new acute myeloid leukemia treatment paths

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and change how blood cells develop.

Continue Reading

News Source: medicalxpress.com